Detailed information for compound 48787
Basic information
Technical information
- TDR Targets ID: 48787
- Name: potassium 2-[[5-ethyl-3-[[4-[2-(2H-tetrazol-5 -yl)phenyl]phenyl]methyl]-1,3,4-thiadiazol-2- ylidene]carbamoyl]cyclopentene-1-carboxylate
- MW: 539.651 | Formula: C25H22KN7O3S
-
H donors: 1
H acceptors: 6
LogP: 4.63
Rotable bonds: 8
Rule of 5 violations (Lipinski): 2 - SMILES: CCc1nn(/c(=N/C(=O)C2=C(CCC2)C(=O)[O-])/s1)Cc1ccc(cc1)c1ccccc1c1n[nH]nn1.[K+]
- InChi: 1S/C25H23N7O3S.K/c1-2-21-29-32(25(36-21)26-23(33)19-8-5-9-20(19)24(34)35)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-30-31-28-22;/h3-4,6-7,10-13H,2,5,8-9,14H2,1H3,(H,34,35)(H,27,28,30,31);/q;+1/p-1/b26-25-;
- InChiKey: IYBVDYGNSNOZHQ-OQKDUQJOSA-M
Network
Hover on a compound node to display the structore
Synonyms
- potassium 2-[[[5-ethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-thiadiazol-2-ylidene]amino]-oxomethyl]-1-cyclopentenecarboxylate
- potassium 2-[[5-ethyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-thiadiazol-2-ylidene]carbamoyl]cyclopentene-1-carboxylate
- potassium 2-[[5-ethyl-3-[4-[2-(2H-tetrazol-5-yl)phenyl]benzyl]-1,3,4-thiadiazol-2-ylidene]carbamoyl]cyclopentene-1-carboxylate
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | angiotensin II receptor, type 1 | Starlite/ChEMBL | References |
| Rattus norvegicus | Type-1B angiotensin II receptor | Starlite/ChEMBL | No references |
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Mycobacterium ulcerans | hypothetical protein | 0.033 | 0.2852 | 0.5 |
| Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.033 | 0.2852 | 0.5 |
| Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0559 | 1 | 1 |
| Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.055 | 0.9706 | 0.9706 |
| Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0559 | 1 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.055 | 0.9706 | 0.9604 |
| Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0559 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0559 | 1 | 1 |
| Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.055 | 0.9706 | 0.9706 |
| Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0559 | 1 | 1 |
| Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.055 | 0.9706 | 0.9706 |
| Onchocerca volvulus | 0.0559 | 1 | 0.5 | |
| Giardia lamblia | Hypothetical protein | 0.033 | 0.2852 | 0.5 |
| Schistosoma mansoni | 6-phosphofructokinase | 0.0559 | 1 | 0.5 |
| Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.033 | 0.2852 | 0.5 |
| Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0559 | 1 | 1 |
| Giardia lamblia | Hypothetical protein | 0.033 | 0.2852 | 0.5 |
| Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.055 | 0.9706 | 0.9706 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (functional) | = 0.4 nM | Antagonist activity at angiotensin AT1 receptor | ChEMBL. | 21071232 |
| IC50 (binding) | = 0.44 nM | Compound was tested in vitro for the ability to displace the specific binding of [125I]-A II from receptors in rat liver membrane(type 1 receptor) | ChEMBL. | No reference |
| IC50 (binding) | = 0.44 nM | Compound was tested in vitro for the ability to displace the specific binding of [125I]-A II from receptors in rat liver membrane(type 1 receptor) | ChEMBL. | No reference |
| Inhibition (functional) | = -0.7 % | In vivo potency of the compound to inhibit the pressor response induced by angiotensin II (100ng/Kg,iv) in conscious normotensive rat at 24 hours after administration of 3 mg/kg, po | ChEMBL. | No reference |
| Inhibition (functional) | = 11.4 % | In vivo potency of the compound to inhibit the pressor response induced by angiotensin II (100ng/Kg,iv) in conscious normotensive rat at 6 hours after administration of 3 mg/kg, po | ChEMBL. | No reference |
| Inhibition (functional) | = 20.7 % | In vivo potency of the compound to inhibit the pressor response induced by angiotensin II (100ng/Kg,iv) in conscious normotensive rat at 24 hours after administration of 0.3 mg/kg, po | ChEMBL. | No reference |
| Inhibition (functional) | = 45.4 % | In vivo potency of the compound to inhibit the pressor response induced by angiotensin II (100ng/Kg,iv) in conscious normotensive rat at 6 hours after administration of 0.3 mg/kg, po | ChEMBL. | No reference |
| Inhibition (functional) | = 57 % | In vivo potency of the compound to inhibit the pressor response induced by angiotensin II (100ng/Kg,iv) in conscious normotensive rat at 24 hours after administration of 1 mg/kg, po | ChEMBL. | No reference |
| Inhibition (functional) | = 72.1 % | In vivo potency of the compound to inhibit the pressor response induced by angiotensin II (100ng/Kg,iv) in conscious normotensive rat at 6 hours after administration of 1 mg/kg, po | ChEMBL. | No reference |
| Reduction (functional) | = 27.2 % | Compound was tested for antihypertensive effect in renal hypertensive rats at 0.3 mg/kg, po expressed as percent reduction in blood pressure | ChEMBL. | No reference |
| Reduction (functional) | = 38.4 % | Compound was tested for antihypertensive effect in renal hypertensive rats at 1 mg/kg, po expressed as percent reduction in blood pressure | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL34866
- PubChem: 23703120
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.